Thermo Fisher Scientific Human IKK beta (C3) Synthetic Peptide

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

-

Blocking Assay (BLOCK)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Class

Synthetic

Type

Peptide

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

purified

Storage buffer

PBS, pH 7.2, with 0.1% BSA

Contains

0.02% sodium azide

Storage conditions

-20°C

Product Specific Information

This peptide corresponds to 19 amino acids near the carboxy terminus of human IKK beta (C3).

PEP-0042 can be used as a blocking peptide with polyclonal antibody PA5-19916.

Target Information

Phosphorylation of serine residues on the I-kappa-B proteins by IKK kinases, including IKBKB, marks them for destruction via the ubiquitination pathway, allowing activation of the NF-kappa-B complex. Inhibitor of nuclear factor kappa-B kinase subunit beta (IKK beta) is a serine kinase that plays an essential role in the NF-kaapa-B signaling pathway which is activated by mulitple stimuli such as inflammatory cytokines, bacterial, or viral products, DNA damages, or other cellular stresses. IKK beta acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Mutations affecting the IKK beta gene can result in Immunodeficiency 15 (IMD15).

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.